Breast Cancer Research volume 21 , Article number: Cite this article. Metrics details. Metastatic triple-negative breast cancer mTNBC , an aggressive histological subtype, has poor prognosis. Chemotherapy remains standard of care for mTNBC, although no agent has been specifically approved for this breast cancer subtype. Atezolizumab in combination with nab-paclitaxel was recently approved for programmed death-ligand 1 PD-L1 —positive locally advanced or metastatic TNBC.
Sexual Problems of Patients With Breast Cancer After Treatment: A Systematic Review
Prognostic models for breast cancer: a systematic review | BMC Cancer | Full Text
Metrics details. Systematic reviews, with or without meta-analysis, play an important role today in synthesizing cancer research and are frequently used to guide decision-making. However, there is now an increase in the number of systematic reviews on the same topic, thereby necessitating a systematic review of previous systematic reviews. With a focus on cancer, the purpose of this article is to provide a practical, stepwise approach for systematically reviewing the literature and publishing the results. This starts with the registration of a protocol for a systematic review of previous systematic reviews and ends with the publication of an original or updated systematic review, with or without meta-analysis, in a peer-reviewed journal.
Prognostic models for breast cancer: a systematic review
Breast cancer is the most common type of cancer in women in the developed world. As a result of breast cancer treatment, many patients suffer from serious complaints in their arm and shoulder, leading to limitations in activities of daily living and participation. In this systematic literature review we present an overview of the adverse effects of the integrated breast cancer treatment related to impairment in functions and structures in the upper extremity and upper body and limitations in daily activities. Patients at highest risk were defined.
Background: Over the last decade, breast cancer surgery has become less invasive and potentially suitable for day surgery. The aim of this systematic review was to establish the benefits and disadvantages of day surgery for breast cancer. All relevant papers were assessed for their methodological quality using a checklist designed to assess both randomised and non-randomised studies with specific questions added to address outcome measures. Results: No randomised controlled trials were found in literature. Eleven observational studies were included.